Marathon Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Marathon Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-33,480	Closed	-$88K	–	144
2019 Q4	$88K	Sell	33,480 -160,100	-83%	-$478K	0.03%	136
2019 Q3	$697K	Sell	193,580 -53,550	-22%	-$190K	0.28%	49
2019 Q2	$832K	Sell	247,130 -114,766	-32%	-$404K	0.34%	46
2019 Q1	$987K	Buy	361,896 +29,850	+9%	+$97.7K	0.44%	37
2018 Q4	$923K	Sell	332,046 -73,000	-18%	-$239K	0.46%	39
2018 Q3	$1.67M	Buy	405,046 +48,242	+14%	+$219K	0.65%	31
2018 Q2	$1.85M	Buy	356,804 +12,400	+4%	+$75.6K	0.7%	29
2018 Q1	$1.89M	Buy	344,404 +86,955	+34%	+$613K	0.74%	27
2017 Q4	$2.1M	Buy	257,449 +5,224	+2%	+$49.9K	0.82%	23
2017 Q3	$2.64M	Buy	252,225 +137,225	+119%	+$1.52M	1.11%	16
2017 Q2	$1.27M	Buy	+115,000	New	+$1.07M	0.6%	33

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marathon Capital Management's ENZ Position: Q1 2020 in Review

Marathon Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q1 2020, closing a stake of 33,480 shares — an estimated $88K sold.

Marathon Capital Management first reported a position in ENZ in Q2 2017 and held it in 11 quarters. The position peaked at $2.64M in Q3 2017. 76 funds tracked by Wall St. Rank hold ENZ as of Q1 2020.

Marathon Capital Management reported no remaining Enzo Biochem, Inc. position as of Q1 2020 after selling out during the quarter.
Marathon Capital Management sold 33,480 Enzo Biochem, Inc. shares in Q1 2020, an estimated $88K.
Marathon Capital Management first reported a position in Enzo Biochem, Inc. in Q2 2017 and held it in 11 quarters.
Marathon Capital Management's Enzo Biochem, Inc. position peaked at $2.64M in Q3 2017.
76 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2020.

Based on Marathon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.